CLIENT SITUATION

● Client had Drug X, an antibody-drug conjugate (ADC), to treat breast cancer patients in Phase II, and wanted to understand its price potential in EU4 and UK.

● The client was expecting a thorough assessment to identify evidence needed to achieve premium price and shape the Phase III study.​​

KEY BUSINESS QUESTIONS

● What is the ADC ex-manufacturer price in EU4+UK?

● What are the typical discounts and rebates offered to payers?

● What price range will be acceptable to payers based on the current Drug X TPP?

● What additional evidence is needed to achieve a premium price point?

● How will the price acceptance change if there is a first launch in the Stage III patient segment?

OUR STRATEGIC APPROACH

● Leveraging desk research and subscribed sources (IHS POLI) to identify ex-manufacturer price of in-market ADCs.​

● Defined price ranges to be tested via Van Westerndorf approach in Payer research to identify acceptable price points for Drug X. Add-on TPP scenarios were tested to understand their impact on discounting/rebate considerations.​

IMPACT

● Drug X’s TPP aligns well with payer expectations. Thus, the drug would be well-positioned to secure acceptance at an accessible annual cost​

● As the Stage III drug launch was on the horizon with an initial discount already expected, we informed our client that payers would likely push for further discount​

Looking to overcome drug commercialization challenges and boost ROI? Fill out the form below to consult with our experts and make informed business decisions.